GLOGRA™ SUSPENSION
Composition : Each 5 ml (teaspoonful) contains :
Fexofinadine Hydrochloride IP 30 mg
In a Flavoured Syrupy base q.s.
Colour : Titanium Dioxide IP
(RASPBERRY VANILLA FLAVOUR)
10 x 1 x 10 SOFT GEL CAP
Description
GLOGRA 30mg Oral Suspension is usually given to children to treat a wide range of symptoms caused due to allergic conditions such as hay fever, urticaria (hives), conjunctivitis (red, itchy eye), and common cold. These symptoms include watery eyes, runny nose, sneezing, and itching among others.
Give GLOGRA 30mg Oral Suspension to your child by mouth with or without food in the dose and way prescribed by the doctor. It may be prescribed alone or in combination with other medicines. The allergic symptoms may subside after your child has taken the initial few doses of GLOGRA 30mg Oral Suspension. In case of serious allergic conditions, your child may have to continue taking the medicine for a week or two. If your child vomits within 30 minutes of taking this medicine, let the child calm down and give the same dose again. However, do not repeat the dose if it is already time for the next dose.
Common side effects
The intake of the medicine may cause some minor and temporary side effects like nausea, vomiting, dizziness, sleepiness, and headache. These side effects should ideally diminish on their own. But, in case they persist or start bothering your child, it would be best to consult your child’s doctor without any delay.
Inform your child’s doctor if your child is on any medical regime or is allergic to any medicine, product, or food. Make sure the doctor knows if your child has or had any heart, liver, kidney problems or was born prematurely. Any history regarding bowel obstruction, malnutrition, weight-related issues, and thyroid problems should also be well indicated to the doctor to avoid any complications in the treatment. Knowing the entire medical history will help your child’s doctor make dose alterations and plan your child’s overall treatment better.
Reviews
There are no reviews yet.